Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Daniel Kollwitz

Nurse Practitioner, Pediatrics Hollywood, FL Nurse Practitioner

NPI 1225196819 CMS profile 10678694

1150 N 35 Ave, Suite 545, Hollywood, FL 33021

Open in the dashboard

General payments

$4,221

215 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Daniel Kollwitz of Hollywood, FL is reported in the CMS Open Payments database as having received $4,221 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $887 40
2023 General $1,380 62
2022 General $898 46
2021 General $1,056 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Kollwitz
  • Nurse Practitioner, Pediatrics median
  • Middle half of Nurse Practitioner, Pediatrics
  • National median

In program year 2025, general payments to Daniel Kollwitz were reported at $0. Among 7,458 Nurse Practitioner, Pediatrics profiles paid that year, the median was $93 and the middle half received between $35 and $201.

Show as a table
Year Daniel Kollwitz Nurse Practitioner, Pediatrics median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $1,056 $60 $23–$142 $132
2022 $898 $72 $27–$161 $149
2023 $1,380 $89 $35–$185 $160
2024 $887 $93 $34–$199 $164
2025 $0 $93 $35–$201 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. Janssen Biotech, Inc. $1,057 54 payments
  2. AbbVie, Inc. $733 39 payments
  3. QOL Medical, LLC $646 43 payments
  4. Genzyme Corporation $464 22 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $250 12 payments
  6. Ipsen Biopharmaceuticals, Inc $186 8 payments
  7. Nestle HealthCare Nutrition Inc. $171 10 payments
  8. Amgen Inc. $144 6 payments
  9. Painteq LLC $116 1 payment
  10. Regeneron Healthcare Solutions, Inc. $81 3 payments
  11. Other $375 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $4,121 214 payments
  2. Education $100 1 payment
Products named General payments · program years 2021–2024
  1. STELARA $1,041 53 payments
  2. HUMIRA $530 31 payments
  3. DUPIXENT $464 22 payments
  4. REMICADE $363 18 payments
  5. SIMPONI ARIA $353 18 payments
  6. Sucraid Therapy For Csid $340 20 payments
  7. SIMPONI $337 17 payments
  8. Sucraid Therapy For Csid $306 23 payments
  9. Bylvay $227 10 payments
  10. RINVOQ $179 7 payments
  11. Other $1,202 50 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record